Skip to main content

Table 1 Patient characteristics

From: Achieving objective response in treatment of non-resectable neuroendocrine tumors does not predict longer time to progression compared to achieving stable disease

 Stz/5-FU n = 32PRRT n = 56Everolimus n = 52
Age, years Median (range)65 (28–83)63 (29–79)66 (41–81)
Sex
 Female20 (63)26 (46)31 (60)
Primary focus (%)
 Pancreas22 (67)18 (32)17 (33)
 Small intestine1 (3)26 (46)19 (37)
 Lung3 (9)1 (2)9(17)
 Rectum1(3)3 (5) 
 Kidney 1(2) 
 Duodenum1(3)1(2) 
 Pheochromocytoma 1(2) 
 Gastric1(3)  
 Thymus  1(2)
 Unknown3 (9)5 (9)6 (12)
Stage
 Regional2 (6)1 (2)4 (8)
 Distant30 (94)55 (98)48 (92)
Previous treatment with PRRT1 (3)25 (48)
Previous treatment with stz/5FU12 (21)18 (35)
Previous treatment with everolimus1 (3)1 (2)
Previous treatment with stz/5FU and PRRT20 (38)
Number of previous treatmentsa Median (mean)0 (0,6)1,9 (2,0)3 (2,6)
Follow-up time Months (min-max)47 (5–113)48 (10–98)14 (4–77)
  1. Patient demographics, site of primary and previous treatments with PRRT, Stz/5FU and everolimus, (percent) and follow-up time (from last CT before initiation of therapy to death or end of study)
  2. a Includes all types of tumor targeted treatments, including surgery